Users' Handbook supplement to the Guidance Document for developing and assessing Adverse Outcome Pathways

In the abstract section, authors should provide a concise and informative summation of the AOP under development that can stand-alone from the AOP page. Abstracts should typically be 200-400 words in length (similar to an abstract for a journal article). Suggested content for the abstract includes the following: (1) the background/purpose for initiation of the AOP’s development (if there was a specific intent); (2) a brief description of the MIE, AO, and/or major KEs that define the pathway; (3) a short summation of the overall WoE supporting the AOP and identification of major knowledge gaps (if any); (4) if a brief statement about how the AOP may be applied (optional). The aim is to capture the highlights of the AOP and its potential scientific and regulatory relevance. Implementation in the AOP-Wiki: https://aopwiki.org/info_pages/2/info_linked_pages/1#E AOP Abstract https://aopwiki.org/info_pages/2/info_linked_pages/1 05%20To%20edit%20AOP%20abstract Background (Optional) This optional subsection should be used to provide background information for AOP reviewers and users that is considered helpful in understanding the biology underlying the AOP and the motivation for its development. The background should NOT provide an overview of the AOP, its KEs or KERs, which are captured in more detail below. A few examples of potential uses of the optional background section include: If the AOP was a result of research funded through a particular grant or research program, the authors may want to provide information regarding the source of funding for the research that led to development of the AOP and the scope and key research questions the over-arching research effort was designed to address. ENV/JM/MONO(2016)12 │ 25 Unclassified If the AOP is one of a series of related AOPs that the author(s) developed as part of a network-guided approach to AOP development, the authors may want to make explicit reference to other AOPs that were also developed as part of the effort in this section. In the case of AOPs that were developed as a regulatory application case study or to support a particular regulatory decision, the authors may want to provide a bit of background on the problem formulation that motivated development of the AOP. If there is some particularly interesting biology that is encompassed by the AOP that is not necessarily evident from the KE and KER descriptions, but would likely be of interest to other investigators with an interest in the AOP, those details could be provided here. In general, this section is suitable for any additional information that does not necessarily fit in other parts of the AOP description, but may be of interest to readers/users. Implementation in the AOP-Wiki: https://aopwiki.org/info_pages/2/info_linked_pages/1#F Background Information